On March 23, 2026, Insmed Inc reported positive results from its Phase 3b ENCORE study, showing ARIKAYCE improved treatment for Mycobacterium avium complex lung infection, with significant efficacy outcomes (p<0.0001 for key metrics). This event is significant as it supports potential FDA approval for the drug, aiming for submission later in 2026.